ABSTRACT N-Acetylmuramyl-L-alanyl-D-isoglutamine and four other synthetic adjuvants that are structural analogs of part of the mycobacterial peptidoglycan monomer are shown to enhance the nonspecific immunity of mice infected by Kiebsiella pneumoniae. These compounds are active by various routes, including oral administration; they are also effective when administered after challenge. Of the seventeen other analogs tested, none is able to increase significantly resistance to infection, although seven of these molecules are adjuvant-active in saline. Previous results have shown that in contrast to lipopolysaccharides, these synthetic adjuvants are devoid of immunogenicity, mitogenicity, and toxicity in normal or adrenalectomized mice.
The host's natural resistance to infection can be increased by previous injection of various bacterial immunostimulants, such as whole mycobacteria (1-4), or lipopolysaccharides (LPS) extracted from Gram-negative organisms (5) (6) (7) (8) . Nonspecific immunity can be enhanced by corynebacteria (9, 10) and other bacterial preparations, such as cord factor (11) (12) (13) or a bacterial phospholipid extract (14) . Administered under adequate conditions, such bacterial agents very markedly increase nonspecific immunity, even against strains made resistant to antibiotics by mutation or plasmid transfer (10) . However, according to previous studies, resistance can be enhanced only if certain time intervals are respected. Thus, BCG (bacillus Calmette-Guerin) has to be administered 2 weeks, corynebacteria approximately 1 week, and LPS between 6 and 48 hr before challenge with Klebsiella pneumoniae (10) . In all cases immunostimulation has to precede inoculation of the virulent organism. For instance, when LPS is administered at the time of or after challenge, it induces a "negative phase" during which the host becomes more susceptible and can even be killed by a nonvirulent strain (5, 6) .
These agents are also endowed with adjuvant activity. Thus, LPS strongly enhances the humoral antibody response (15) and mycobacteria administered in Freund's complete adjuvant increase circulating antibodies and induce delayed hypersensitivity (16) . The active fraction responsible for the activity of mycobacteria in Freund's complete adjuvant is related to a water-soluble component of the cell wall, which was called water-soluble adjuvant and has a molecular weight of approximately 20 ,000 (17, 18 (26, 27) . The effect of water-soluble adjuvant on the susceptibility of mice to infection with four challenge organisms was previously studied. An intravenous dose of 1 mg of water-soluble adjuvant per mouse 24 hr before challenge significantly prolongs the length of the survival time, although no definitive survival could be observed (28) .
More recently, we have reported that muramyl dipeptide and an adjuvant-active analog, N-acetylmuramyl-L-alanyl-D-glutamic acid (muramyl dipeptide acid) were also capable of enhancing nonspecific resistance to infection against K. pneumoniae. Whereas two stereoisomers lacking adjuvant activity did not protect the infected mice, muramyl dipeptide is active by various routes, including orally, and even if administered after the challenge (29) . In the present study, we have extended this investigation and assayed the activity of 22 analogs against K. pneumoniae infection.
MATERIALS AND METHODS
Mice. (C57B1/6 X AKR)F1 hybrids (5-6 weeks Synthetic Glycopeptides. Most of the synthetic analogs were prepared as described (31) . Methods for preparation of com-2089 2090 Immunology: Chedid et al. pounds 13, 16 , and 22 will be published later. The following compounds were used:
(
Treatment of Animals. All preparations were administered in apyrogenic saline either parenterally in a volume of 0.2 ml or orally in 0.5 ml. The cord factor preparation was injected suspended in water by the method of Kato (32) .
Infectious Challenge. A K. pneumoniae strain of capsular type 2 (10) was used in this study (the median lethal dose was about 102 bacteria when given intravenously and about 103 bacteria when given intramuscularly). This strain is less virulent than the Caroli strain of K. pneumoniae (KpC) previously used in certain studies. With KpC all controls challenged with 102 organisms are killed within 24 hr (8) .
Cumulative results of several comparable experiments (with groups of eight mice each time) were expressed as the percentage of survival. The P values were obtained by using the adjusted chi-square method (33). Table 1 represent the cumulative numbers of survivors in treated groups compared to their respective controls. Groups treated by glycopeptides that were found to be inactive (see Table 5 ) have been omitted from Table 1 , were inactive (see Table 5 ). Table 2 represent the cumulative 
* Administered alone in saline. Protective activity of synthetic glycopeptides in mice infected intravenously In the following experiment all mice were challenged by intravenous administration of Klebsiella. In separate experiments, which are not represented in Table 4 , a significant prolongation of survival time was observed when muramyl dipeptide was administered intravenously or orally 24 hr before an intravenous challenge by 105 organisms. However, very few treated mice survived at day 3. Therefore, mice were treated intravenously 24 hr before they were infected with 103 Kiebsiella. In contrast to the previous experiments, they were challenged intravenously. In addition to the saline-treated controls, several groups received synthetic glycopeptides, or killed BCG cells, or cord factor, or lipopolysaccharides administered in the same way. Two groups, moreover, were treated orally by muramyl dipeptide or by BCG.
As shown in Table 4 , LPS or BCG were very effective when given intravenously. A highly significant protection was also observed in mice treated intravenously with the four synthetic glycopeptides. Moreover, muramyl dipeptide administered orally was also very effective, whereas BCG administered orally was inactive. Cord factor suspended in saline was inactive when administered only 24 hr before challenge. This result is in agreement with a previous report in which this compound has been shown to protect mice only if administered at a greater time interval before infection (12) .
Correlation between anti-infectious and adjuvant activities of synthetic glycopeptides
As can be seen in Table 5 , 12 of the 22 molecules tested were found to be adjuvant-active. Therefore, although the five analogs that increased resistance to infection were adjuvant-active in saline, several others (7, 8, 14, 15, 17, 19, and 22 ) that increased the immune response did not enhance nonspecific resistance against Klebsiella. DISCUSSION The data reported here show that five synthetic adjuvants, structural analogs of a part of the mycobacterial peptidoglycan monomer, are capable of increasing the host's nonspecific resistance against a K. pneumoniae infection. It has been shown (under different experimental conditions) that optimal activity is observed if BCG or other mycobacterial preparations are administered 2 or 3 weeks prior to challenge (1, 2, 10) . In agreement is our present finding showing that cord factor has no activity if injected 1 day before infection. However, both synthetic analogs and BCG protected mice if administered 1 day prior to or even 1 hr after challenge. We have also observed, in preliminary experiments that will be reported later, that: these synthetic adjuvants are devoid of bactericidal or bacteriostatic activity in vitro and muramyl dipeptide prevents the death of mice infected with K. pneumoniae organisms rendered resistant to streptomycin by plasmid transfer, whereas controls can no longer be protected in vivo by this antibiotic.
Of the 22 molecules tested, 17 had no significant antiKlebsiella activity; of these 17, 10 were also devoid of adjuvant activity. Because of the extraordinary effectiveness of LPS in all similar experimental systems, it is essential to consider the possibility of endotoxin contamination. Pyrogenicity, one of the prominent properties of LPS, has been detected in rabbits with high dosages of muramyl dipeptide or of analog 13. However, compound 14, which is also pyrogenic (34), did not protect mice against the infectious challenge, whereas compound 2, which is nonpyrogenic (34), increases nonspecific resistance to Klebsiella (see Table 5 ). Other assays, which will be published separately, also show that there exists no close Proc. Nati. Acad. Sci. USA 74 (1977) Proc. Nati. Acad. Sci. USA 74 (1977) 2093 relationship between pyrogenicity and enhancement of nonspecific immunity. The following facts also argue against the possibility of an endotoxin-like activity. In contrast to LPS, muramyl dipeptide was devoid of mitogenic or toxic activity in normal or adrenalectomized mice and was negative in the Limulus amebocyte lysate test (unpublished results) and the synthetic molecules are active when administered orally (26, 
24).
Our results (Table 5) suggest the following tentative correlation between chemical structure and antibacterial activity. All compounds active in the anti-Klebsiella test described here have the same structure and the same stereochemistry as that found in muramyl dipeptide, i.e., L-Ala-D-Glu. Replacement of the L-alanyl residue by L-seryl or glycyl residue gives adjuvant-active compounds, but their activity in the anti-Klebsiella test was not statistically significant;
The nature of the substituents of the carboxyl groups of the glutamyl residue is also critical. A free a-carboxyl function, an a-methyl ester, or an a-carboxamide group gives both activities, whereas N-methylation of the a-carboxamide group weakens only anti-Klebsiella activity. On the other hand, the presence of an L-lysyl residue on the y-carboxyl gives a compound active in both tests. A further substitution of L-lysyl by D-alanyl weakens the anti-Klebsiella activity but not the adjuvant activity. Thus, the anti-Klebsiella activity seems to be more specific than the adjuvant activity.
The extraordinary effectiveness of LPS and other bacterial agents in amplifying nonspecific immune responses has been extensively documented. Their utilization other than in experimental procedures has been greatly restricted by their various side effects, such as tuberculin sensitization in the case of mycobacteria and marked pyrogenicity and toxicity in human beings in the case of LPS. Our present findings show that nonimmunogenic synthetic analogs of the mycobacterial cell wall peptidoglycan that are devoid of toxicity in several animal species protected effectively against an unrelated infection even if administered orally. Mice were also cured when these compounds were administered after challenge. Such compounds could therefore constitute potential tools for clinical application.
